RxElite, Inc. Stock

Equities

RXEI

US78347X1054

Pharmaceuticals

Market Closed - OTC Markets 03:17:56 2023-04-03 pm EDT 5-day change 1st Jan Change
0.000001 USD -.--% Intraday chart for RxElite, Inc. -.--% -.--%
Sales 2006 14.17M Sales 2007 2.81M Capitalization 84.94M
Net income 2006 7M Net income 2007 -17M EV / Sales 2006 * -
Net cash position 2006 789K Net cash position 2007 8.6M EV / Sales 2007 27.1 x
P/E ratio 2006 *
-
P/E ratio 2007
-3.2 x
Employees 47
Yield 2006 *
-
Yield 2007
-
Free-Float 68.17%
More Fundamentals * Assessed data
Dynamic Chart
3 years
0.00
Extreme 0
0.00
5 years
0.00
Extreme 0
0.00
10 years
0.00
Extreme 0
0.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 52 07-07-12
More insiders
RxElite, Inc. (RxElite) develops and markets generic prescription drug products in specialty generic markets. RxElite's markets and pipeline products are in specialty markets. These markets include specialty products in the areas of anesthesia gases, sterile liquid dose products, which includes ophthalmic products, sterile inhalation respiratory products and injectable, drugs and active pharmaceutical ingredients (APIs). The Company's customers include hospitals and hospital group purchasing organizations, national and regional wholesalers, direct retail pharmacy stocking chains, homecare companies, and outpatient surgery centers and ambulatory care clinics. In January 2008, RxElite acquired FineTech Laboratories, Ltd, which manufactures APIs in its facility in Haifa, Israel. In January 2009, RXElite announced the sale of all the issued and outstanding capital stock of RxElite Holdings Inc. (Holdings), its wholly owned United States subsidiary, to Piramal Healthcare Limited.
More about the company